Measuring bronchodilation in COPD clinical trials

Zoë L. Borrill, C. M. Houghton, A. A. Woodcock, J. Vestbo, D. Singh

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Aims: The aim of this study was to compare the variability and sensitivity of impulse oscillometry (R5, X5 and RF), plethysmography (Raw and sGaw) and spirometry (FEV1, FVC and MMEF) in order to determine the most powerful technique for assessing bronchodilation in COPD clinical trials. Methods: Twenty‐four patients with COPD had impulse oscillometry, plethysmography and spirometry measured twice 30 mins apart, to determine variability. Then ascending doses of salbutamol (20, 50, 100, 200, 400 and 800 µg) were given and the same measurements made after each dose. Significant changes greater than variability were determined for each performed measurement (expressed as mean percentage improvement with 95% CI). Results: Significant effects (P < 0.05) were detected after 20 µg by X5 (18.5% CI 9.8–27.2) RF (11.1% CI 7.2–15.0) and sGaw (21.5% CI 10.1–32.9), and after 50 µg by R5 (16.7% CI 10.8–22.5) and Raw (19.7% CI 13.0–26.4). FEV1 was less sensitive, detecting significant bronchodilation at 100 µg (10.2% CI 7.4–12.9). Conclusions: We conclude that impulse oscillometry and plethysmography should be considered the preferred techniques for measuring bronchodilation in COPD clinical trials.
OriginalsprogEngelsk
TidsskriftBritish Journal of Clinical Pharmacology
Vol/bind59
Udgave nummer4
Sider (fra-til)379-384
Antal sider6
ISSN0306-5251
DOI
StatusUdgivet - apr. 2005
Udgivet eksterntJa

Fingeraftryk

Oscillometry
Plethysmography
Chronic Obstructive Pulmonary Disease
Clinical Trials
Albuterol

Emneord

  • Bronchodilation
  • Clinical trials
  • COPD

Citer dette

Borrill, Zoë L. ; Houghton, C. M. ; Woodcock, A. A. ; Vestbo, J. ; Singh, D. / Measuring bronchodilation in COPD clinical trials. I: British Journal of Clinical Pharmacology. 2005 ; Bind 59, Nr. 4. s. 379-384.
@article{7fde58231cbd452dbeca6792f362930d,
title = "Measuring bronchodilation in COPD clinical trials",
abstract = "Aims: The aim of this study was to compare the variability and sensitivity of impulse oscillometry (R5, X5 and RF), plethysmography (Raw and sGaw) and spirometry (FEV1, FVC and MMEF) in order to determine the most powerful technique for assessing bronchodilation in COPD clinical trials. Methods: Twenty‐four patients with COPD had impulse oscillometry, plethysmography and spirometry measured twice 30 mins apart, to determine variability. Then ascending doses of salbutamol (20, 50, 100, 200, 400 and 800 µg) were given and the same measurements made after each dose. Significant changes greater than variability were determined for each performed measurement (expressed as mean percentage improvement with 95{\%} CI). Results: Significant effects (P < 0.05) were detected after 20 µg by X5 (18.5{\%} CI 9.8–27.2) RF (11.1{\%} CI 7.2–15.0) and sGaw (21.5{\%} CI 10.1–32.9), and after 50 µg by R5 (16.7{\%} CI 10.8–22.5) and Raw (19.7{\%} CI 13.0–26.4). FEV1 was less sensitive, detecting significant bronchodilation at 100 µg (10.2{\%} CI 7.4–12.9). Conclusions: We conclude that impulse oscillometry and plethysmography should be considered the preferred techniques for measuring bronchodilation in COPD clinical trials.",
keywords = "Bronchodilation, Clinical trials, COPD",
author = "Borrill, {Zo{\"e} L.} and Houghton, {C. M.} and Woodcock, {A. A.} and J. Vestbo and D. Singh",
year = "2005",
month = "4",
doi = "10.1111/j.1365-2125.2004.02261.x",
language = "English",
volume = "59",
pages = "379--384",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "4",

}

Measuring bronchodilation in COPD clinical trials. / Borrill, Zoë L.; Houghton, C. M.; Woodcock, A. A.; Vestbo, J.; Singh, D.

I: British Journal of Clinical Pharmacology, Bind 59, Nr. 4, 04.2005, s. 379-384.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Measuring bronchodilation in COPD clinical trials

AU - Borrill, Zoë L.

AU - Houghton, C. M.

AU - Woodcock, A. A.

AU - Vestbo, J.

AU - Singh, D.

PY - 2005/4

Y1 - 2005/4

N2 - Aims: The aim of this study was to compare the variability and sensitivity of impulse oscillometry (R5, X5 and RF), plethysmography (Raw and sGaw) and spirometry (FEV1, FVC and MMEF) in order to determine the most powerful technique for assessing bronchodilation in COPD clinical trials. Methods: Twenty‐four patients with COPD had impulse oscillometry, plethysmography and spirometry measured twice 30 mins apart, to determine variability. Then ascending doses of salbutamol (20, 50, 100, 200, 400 and 800 µg) were given and the same measurements made after each dose. Significant changes greater than variability were determined for each performed measurement (expressed as mean percentage improvement with 95% CI). Results: Significant effects (P < 0.05) were detected after 20 µg by X5 (18.5% CI 9.8–27.2) RF (11.1% CI 7.2–15.0) and sGaw (21.5% CI 10.1–32.9), and after 50 µg by R5 (16.7% CI 10.8–22.5) and Raw (19.7% CI 13.0–26.4). FEV1 was less sensitive, detecting significant bronchodilation at 100 µg (10.2% CI 7.4–12.9). Conclusions: We conclude that impulse oscillometry and plethysmography should be considered the preferred techniques for measuring bronchodilation in COPD clinical trials.

AB - Aims: The aim of this study was to compare the variability and sensitivity of impulse oscillometry (R5, X5 and RF), plethysmography (Raw and sGaw) and spirometry (FEV1, FVC and MMEF) in order to determine the most powerful technique for assessing bronchodilation in COPD clinical trials. Methods: Twenty‐four patients with COPD had impulse oscillometry, plethysmography and spirometry measured twice 30 mins apart, to determine variability. Then ascending doses of salbutamol (20, 50, 100, 200, 400 and 800 µg) were given and the same measurements made after each dose. Significant changes greater than variability were determined for each performed measurement (expressed as mean percentage improvement with 95% CI). Results: Significant effects (P < 0.05) were detected after 20 µg by X5 (18.5% CI 9.8–27.2) RF (11.1% CI 7.2–15.0) and sGaw (21.5% CI 10.1–32.9), and after 50 µg by R5 (16.7% CI 10.8–22.5) and Raw (19.7% CI 13.0–26.4). FEV1 was less sensitive, detecting significant bronchodilation at 100 µg (10.2% CI 7.4–12.9). Conclusions: We conclude that impulse oscillometry and plethysmography should be considered the preferred techniques for measuring bronchodilation in COPD clinical trials.

KW - Bronchodilation

KW - Clinical trials

KW - COPD

U2 - 10.1111/j.1365-2125.2004.02261.x

DO - 10.1111/j.1365-2125.2004.02261.x

M3 - Journal article

VL - 59

SP - 379

EP - 384

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 4

ER -